Previous 10 |
- Healthcare institutional investors and insiders commit $15 million through private investment in public equity (“PIPE”) - - Lincoln Park Capital has committed to purchase up to $50 million of common stock - - Proceeds to advance the Phase 2 deve...
NEW YORK, NY and SHANGHAI, CHINA, May 03, 2019 (GLOBE NEWSWIRE) -- The special meeting (the “ Special Meeting ”) of shareholders of Bison Capital Acquisition Corp. (“ BCAC ”, NASDAQ: BCAC), originally scheduled to be held on May 13, 2019 at 9:00 a.m., Beiji...
NEW YORK, NY and SHANGHAI, CHINA, April 29, 2019 (GLOBE NEWSWIRE) -- Bison Capital Acquisition Corp. (“ BCAC ”, NASDAQ: BCAC) announced today, that it has established a record date of April 5, 2019 for a special meeting of its shareholders to be held on May 13, 2019 at 9:00 a....
RALEIGH, N.C. and SHANGHAI , March 20, 2019 /PRNewswire/ -- Xynomic Pharmaceuticals, Inc. ("Xynomic"), a clinical stage US-China oncology drug development company, and Bison Capital Acquisition Corporation (Nasdaq: BCAC), jointly announced that Xynomic and its collaborators will pr...
RALEIGH, N.C. and SHANGHAI , March 16, 2019 /PRNewswire/ -- Xynomic Pharma, a clinical stage US-China oncology drug development company, and Bison Capital Acquisition Corp. (Nasdaq: BCAC), today jointly announced that China , Spain and Poland authorities have approved Xynomic'...
Deals and Financings NJCTTQ, a Nanjing biopharma, announced a deal worth up to $4 billion to co-develop bispecific immunotherapies discovered by Abpro of Massachusetts. NJCTTQ will have China and Thai rights to multiple immunotherapies discovered by Abpro's DiversImmune antibody discovery ...
RALEIGH, N.C. and SHANGHAI , Feb. 23, 2019 /PRNewswire/ -- Xynomic Pharma, a clinical stage US-China oncology drug development company, and Bison Capital Acquisition Corp. (Nasdaq: BCAC), today jointly announced the dosing of the first South Korean patient at the Asan Medical Cente...
News, Short Squeeze, Breakout and More Instantly...
Bison Capital Acquisition Corp. Company Name:
BCAC Stock Symbol:
NASDAQ Market:
SAN CARLOS, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (“Apexigen”), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that Apexigen’s Manageme...
SAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (“Apexigen”), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of William Duke...
- Data from the Parker Institute for Cancer Immunotherapy and Cancer Research Institute multi-center Phase 2 PRINCE trial demonstrated that novel circulating and tumor biomarkers may be predictive of overall survival - - Identified distinct immune responses and biomarkers in...